RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ultragenyx Pharmaceutical Inc. (RARE) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including insider selling, class action lawsuits, and declining financial metrics. While there are some positive catalysts like ongoing restructuring and potential clinical data in 2H26, these are not immediate drivers for stock growth. The technical indicators and options data suggest a neutral to bearish sentiment, and there are no strong trading signals from Intellectia Proprietary Trading Signals. A hold action is recommended at this time.
The technical indicators for RARE are bearish. The MACD is below zero and negatively contracting, suggesting downward momentum. The RSI is neutral at 43.008, offering no clear signal. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5. Key support is at 20.375, and resistance is at 24.443. The stock is trading below its pivot level of 22.409, indicating weakness.
Restructuring initiatives to reduce costs and streamline operations, potentially paving the way for profitability in
Positive expectations for Phase 3 GTX-102 data for Angelman syndrome in 2H
Revenue growth of 25.55% YoY in Q4 2025 driven by Crysvita and Dojolvi.
Insider selling has increased by 2368.07% over the last month.
Multiple class action lawsuits alleging securities violations and misleading investors about drug efficacy.
Declining financial metrics, including a drop in net income, EPS, and gross margin.
Analysts have significantly lowered price targets across the board.
No recent congress trading data or influential figure activity to support the stock.
In Q4 2025, revenue increased by 25.55% YoY to $207M, but net income dropped by -3.29% YoY to -$129M. EPS declined by -7.19% YoY to -1.29, and gross margin fell by -4.19% YoY to 85.99. While revenue growth is positive, the company remains unprofitable with declining margins.
Analysts have lowered price targets significantly, with targets now ranging from $34 to $79. Most analysts maintain a Buy or Outperform rating, citing long-term potential from clinical data and restructuring efforts. However, short-term risks, including regulatory uncertainty and uneven revenue patterns, weigh heavily on the stock.
